Palbociclib Pfizer

Menu

Close

HomeAboutMode of actionEfficacyPALOMA-2Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)PALOMA-3Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)Real World EvidenceP-REALITY study designP-REALITY patients characteristicsP-REALITY real-world progression-free survivalP-REALITY overall survivalP-REALITY strengthsSafetyImportant Safety InformationSafetySafety overviewPooled ARsPooled laboratory abnormalitiesPALOMA-2 AEsPALOMA-3 AEsSelected safety featuresPalbociclib long-term safetyGI and liver toxicitiesEffect of Palbociclib on QTc intervalElderly patientsVisceral disease patientsDose reduction effect on efficacyDosingRecommended dosing scheduleRecommended dose modifications for AEsOne scheduled monitoring provisionMedical InformationVisit the Pfizer Medical Information Africa Website for Healthcare ProfessionalsSubmit a medical question to Pfizer

To report an adverse event, please contact [email protected]
P-Reality study design

P-REALITY (Palbociclib REAL-world 1st-line ComparaTive Effectiveness StudY) was a comparison of the effectiveness of 1st-line Palbociclib Pfizer in combination with letrozole vs 
letrozole alone1

P-REALITY study design​​​​​​​

A total of 1430 patients with ≥3 months of follow-up received Palbociclib Pfizer in combination with letrozole or letrozole alone in the 1st-line setting1

sIPTW was used to balance patient characteristics and minimise bias caused by lack of randomisation*1

Approaches to minimise bias due to lack of randomisation1
HR+/HER2- = hormone receptor-positive, human epidermal growth factor receptor 2-negative; LET = letrozole; mBC = metastatic breast cancer; N/n = number of patients; OS = overall survival; PFS = progression-free survival; RCT = randomised controlled trial; sIPTW = stabiIised inverse probability treatment weighting.References:DeMichele A, et al. Breast Cancer Res. 2021;23:37.
Austin PC, Stuart EA. Stat Med. 2015;34(28):3661-3679. 
EffectivenessPALOMA-2 Patient baseline characteristics Learn more

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

This site is intended only for Rwanda health care professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2022 Pfizer Inc. All rights reserved.

Disclaimer: The product is not yet licensed by the Board of Health of Rwanda (Rwanda FDA). The product has however obtained prior Board of Health approval for supply to Accord program channels in Rwanda.

You are now leaving Accord Portal to access Pfizer Medical Information Portal  You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.